Using Molecular GI Testing to Improve Laboratory Efficiency and Patient Management

Discover Molecular GI Testing Benefits

Gastrointestinal infections challenge the healthcare system, creating a major burden for hospitals both operationally and financially. Traditional diagnostic methods such as culture, microscopy, and immunoassays come with limitations that can impact laboratory operations, clinical decision making, and patient outcomes. 

Implementing molecular testing methods for GI pathogens can give you shorter turnaround times and may require less hands-on attention in the lab. This can help you increase diagnostic accuracy to provide patients with more definitive diagnoses and the ability to spend less time in the hospital.

In this webinar, you’ll hear from an experienced medical microbiologist and learn about their selection criteria for molecular panels for GI testing, the impact it has had on their laboratory and patients, and the role diagnostic stewardship plays in their laboratory testing practices.

Learning Objectives

This webinar will help you:

• Discuss the impact of targeted enteric panels on laboratory workflows and patient management
• Review considerations for diagnostic stewardship in molecular GI testing
• Identify the factors that lead to the selection of different molecular panels

Watch on Demand       Download Slides (PDF, 4.4MB)

For research use only. Not for diagnostic procedures.

Jennifer Dien Bard PhD, D(ABMM), FIDSA, FAAM, Professor of Pathology at the University of Southern California and Director of the Clinical Microbiology and Virology Laboratories at Children’s Hospital Los Angeles

Dr. Dien Bard has published over 100 scientific papers in the past decade and frequently presents about rapid molecular diagnostics. She has received funding from multiple agencies, including the National Institutes of Health and those in the diagnostics industry. Her clinical research studies explore the application and effects of laboratory diagnostics, particularly molecular diagnostics, on antimicrobial utilization and overall patient outcome. She serves on several committees and working groups, including the National Academy of Sciences (NAS), the Infectious Diseases Society of America (IDSA), the Association for Molecular Pathology (AMP), the American Society for Microbiology (ASM), the Clinical and Laboratory Standards Institute (CLSI), and the Antimicrobial Resistance Leadership Group (ARLG). Dr. Dien Bard was recently elected as a Fellow of the American Academy of Microbiology, a great honor in the field of microbial sciences.